Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C

Liver International

Volumn 29, Issue 7, 2009, Pages 1086-1093

  Hung, Chao Hung ^a   Lee, Chuan Mo ^a   Chen, Chien Hung ^a   Hu, Tsung Hui ^a   Jiang, Shu Rong ^a   Wang, Jing Houng ^a   Lu, Sheng Nan ^a   Wang, Pei Wei ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Adiponectin; Fatty liver; Hepatitis C virus; Insulin resistance; Interleukin 10; Interleukin 6; Steatosis; Tumour necrosis factor

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT;

ADIPONECTIN; ADULT; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; INTERLEUKIN-10; INTERLEUKIN-6; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VIRAL LOAD;

EID: 67650501133     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.01991.x     Document Type: Article

References (46)

1. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. Natl Heart, Lung, Blood Inst Study Group N Engl J Med 1992; 327: 1906-11.
2. Poynard T, Bedossa P, Oplon P. For the OBSTIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Nature history of liver fibrous progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
3. Hung CH, Chen CH, Lee CM, et al. Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma. J Viral Hepat 2008; 15: 58-65.
4. Gumber SC, Chopra S. Hepatitis C: A multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123: 615-20.
5. Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepat 1997; 4: 9-28.
6. Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-63.
7. Mehta SH, Brancati FL, Strathdee SA, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38: 50-6.
8. Huang JF, Dai CY, Hwang SJ, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: An epidemiological link with virological implication. Am J Gastroenterol 2007; 102: 1237-43.
9. Petit JM, Bour JB, Galland-Jos C, et al. Risk factor for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 2001; 35: 279-83.
10. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 2003; 125: 1695-704.
11. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
12. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/ PI3-kinase signalling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 1384-92.
13. Hung CH, Lee CM, Kuo FY, et al. Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor-kappa B in chronic hepatitis C. Liver Int 2008; 28: 339-46.
14. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study. Lancet 1999; 353: 1649-52.
15. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34.
16. Festa A, D'Agostino Jr R, Tracy RP, Haffner SM. Insulin resistance atherosclerosis study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-7.
17. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-potsdam study. Diabetes 2003; 52: 812-7.
18. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391-9.
19. Knobler H, Zhornicky T, Sandler A, et al. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 2003; 98: 2751-6.
20. Maeno T, Okumura A, Ishikawa T, et al. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2003; 18: 1358-63.
21. Lecube A, Hernández C, Genescà J, Simó R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study. Diabetes Care 2006; 29: 1096-101.
22. Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 2007; 46: 66-73.
23. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
24. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 200-6.
25. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
26. van Exel E, Gussekloo J, de Craen AJ, et al. Leiden 85 plus study. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: The leiden 85-plus study. Diabetes 2002; 51: 1088-92.
27. Liu CJ, Chen PJ, Jeng YM, et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005; 43: 235-42.
28. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.
29. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
30. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR cooperative study group. Hepatology 1994; 20: 15-20.
31. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
32. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: Modifiable and nonmodifiable factors. Gastroenterology 2008; 134: 1699-714.
33. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-23.
34. Tacke F, Wüstefeld T, Horn R, et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005; 42: 666-73.
35. Kaser S, Moschen A, Kaser A, et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 2005; 258: 274-80.
36. Kaser S, Moschen AR, Cayon A, et al. Adiponectin and its receptors in nonalcoholic steatohepatitis. Gut 2005; 54: 117-21.
37. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004; 40: 46-54.
38. Garaulet M, Hernández-Morante JJ, de Heredia FP, Tébar FJ. Adiponectin, the controversial hormone. Public Health Nutr 2007; 10: 1145-50.
39. Jonsson JR, Moschen A, Hickman IJ, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005; 43: 929-36.
40. Lu JY, Chuang LM, Yang WS, et al. Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. Liver Int 2005; 25: 752-9.
41. Siagris D, Vafiadis G, Michalaki M, et al. Serum adiponectin in chronic hepatitis C and B. J Viral Hepat 2007; 14: 577-83.
42. Hsu CS, Liu CJ, Liu CH, et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int 2008; 28: 271-7.
43. Anty R, Gelsi E, Giudicelli J, et al. Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses. Eur J Gastroenterol Hepatol 2007; 19: 671-7.
44. Marín-Serrano E, Rodríguez-Ramos C, Díaz F, Martín-Herrera L, Girón-González JA. Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. J Viral Hepat 2006; 13: 230-4.
45. Chang AM, Smith MJ, Bloem CJ, et al. Limitation of the homeostasis model assessment to predict insulin resistance and beta-cell dysfunction in older people. J Clin Endocrinol Metab 2006; 91: 629-34.
46. Spahr L, Giostra E, Frossard JL, et al. Soluble TNF-R1, but not tumor necrosis factor alpha, predicts the 3-month mortality in patients with alcoholic hepatitis. J Hepatol 2004; 41: 229-34.